...The parties expanded a 2007 deal that granted HepaLife exclusive rights to the USDA's PICM-19 hepatocyte... ...such as malaria (see BioCentury, Nov. 12, 2007). HepaLife Technologies Inc. (OTCBB:HPLF; FSE:HL1), Boston, Mass. U.S. Department of Agriculture...
...HPLF received exclusive rights to the USDA's PICM-19 hepatocyte cell lines to develop and commercialize artificial... ...toxicological testing platforms. Further terms were not disclosed. HepaLife Technologies Inc. (HPLF; FSE:HL1), Boston, Mass. U.S. Department of Agriculture...
...Researchers from the U.S. Department of Agriculture, Kirin (Tokyo:2503; KNBWY) and colleagues reported in Nature Biotechnology the generation and...
...The parties expanded a 2007 deal that granted HepaLife exclusive rights to the USDA's PICM-19 hepatocyte... ...such as malaria (see BioCentury, Nov. 12, 2007). HepaLife Technologies Inc. (OTCBB:HPLF; FSE:HL1), Boston, Mass. U.S. Department of Agriculture...
...HPLF received exclusive rights to the USDA's PICM-19 hepatocyte cell lines to develop and commercialize artificial... ...toxicological testing platforms. Further terms were not disclosed. HepaLife Technologies Inc. (HPLF; FSE:HL1), Boston, Mass. U.S. Department of Agriculture...
...Researchers from the U.S. Department of Agriculture, Kirin (Tokyo:2503; KNBWY) and colleagues reported in Nature Biotechnology the generation and...